| Ytd | -27.41% | |
| 1y | -22.32% |
| Open | 13.42 | Prev Close | 13.35 | Low | 13.30 | High | 13.49 | Mkt Cap | 173.00M |
| Vol | 81.94K | Avg Vol | 90.50K | EPS | -2.16 | P/E | N/A | Forward P/E | -7.96 |
| Beta | 0.84 | Short Ratio | 18.59 | Inst. Own | 45.50% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-19 | 50-d Avg | 13.78 | 200-d Avg | 16.08 | 1yr Est | 29.00 |
Independent DSMB Recommends MediWound's EscharEx ® Phase III VALUE Study Continue Without Modificati
MediWound to Present at the H.C. Wainwright 28 th Annual Global Investment Conference YAVNE, Israel,
Oppenheimer analyst Jeff Jones maintains MediWound (NASDAQ:MDWD) with a Outperform and lowers the
MediWound Ltd. (MDWD) Q2 2026 Earnings Call Transcript
MediWound NASDAQ: MDWD reported second-quarter 2026 revenue of $3.1 million, down from $5.7 million
MediWound (NASDAQ:MDWD) held its second-quarter earnings conference call on Thursday. Below is the c
MediWound (MDWD) came out with a quarterly loss of $0.77 per share versus the Zacks Consensus Estima
MediWound (NASDAQ:MDWD) reported quarterly losses of $(0.77) per share which missed the analyst cons
MediWound (NASDAQ:MDWD) affirms FY2026 sales outlook from $24.000 million-$26.000 million to $24.000
EscharEx ® Phase III VALUE Trial Advancing; Interim Assessment and Enrollment Completion Expected by
MediWound to Report Second Quarter 2026 Financial Results Conference Call and Webcast Scheduled for
Oppenheimer analyst Francois Brisebois maintains MediWound (NASDAQ:MDWD) with a Outperform and lo
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates MediWound (NASDAQ:MDWD) with a
MediWound Ltd. (MDWD) Q1 2026 Earnings Call Transcript
MediWound NASDAQ: MDWD reported a wider first-quarter loss and lower revenue compared with the prior
MediWound (MDWD) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estima
MediWound (NASDAQ:MDWD) affirms FY2026 sales outlook from $24.000 million-$26.000 million to $24.000
MediWound (NASDAQ:MDWD) reported quarterly losses of $(0.23) per share which beat the analyst consen
EscharEx ® Phase III VALUE trial advancing; interim assessment and enrollment completion expected by
MediWound to Report First Quarter 2026 Financial Results Conference Call and Webcast Scheduled for W
Surrozen (NASDAQ: SRZN - Get Free Report) and MediWound (NASDAQ: MDWD - Get Free Report) are both sm
Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement
MediWound to Present New EscharEx ® Data at Leading Wound Care Conferences Data highlights mechani
Dyne Therapeutics (NASDAQ: DYN - Get Free Report) and MediWound (NASDAQ: MDWD - Get Free Report) are
MediWound Reports BARDA Contract Award to Vericel for NexoBrid ® Valued at up to $197 Million YAVNE,
MediWound Ltd. (MDWD) Q4 2025 Earnings Call Transcript
MediWound Files Annual Report on Form 20-F YAVNE, Israel, March 5 , 202 6 -- MediWound Ltd. (Nasdaq:
MediWound (MDWD) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estima
MediWound (NASDAQ:MDWD) affirms FY2028 sales outlook from $50.000 million-$55.000 million to $50.000
MediWound (NASDAQ:MDWD) affirms FY2027 sales outlook from $32.000 million-$35.000 million to $32.000
MediWound (NASDAQ:MDWD) affirms FY2026 sales outlook from $24.000 million-$26.000 million to $24.000
MediWound (NASDAQ:MDWD) reported quarterly losses of $(0.56) per share which beat the analyst consen
Shares of Sharps Technology, Inc. (NASDAQ:STSS) rose sharply in today's pre-market trading after
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarte
Companies Reporting Before The Bell • Golden Ocean Group (NASDAQ:GOGL) is likely to report quarterl
Friday's session saw 225 companies set new 52-week lows.
On Thursday, 283 companies set new 52-week lows.
On Wednesday, 179 companies reached new 52-week lows.
Companies Reporting Before The Bell • KVH Industries (NASDAQ:KVHI) is projected to report quarterly